Latest Immunotherapy Treatments

Biomarker CD47 as a Successful Diagnostic and Treatment Tool

Survival rates for diffuse mesothelioma are notoriously low with the median survival ranging between 12 to 22 months.  A contributing factor to treatment being ineffective is that the disease if often in the advanced stages by the time it is noticed and diagnosed. Early detection may be a key factor[…]

Read More »

Clinical Trial Investigates Multimodality Treatment for Pleural and Peritoneal Mesothelioma

Researchers at the Memorial Sloan Kettering Cancer Center are collaborating with Pfizer to study the effects of immunotherapy treatment Avelumab when combined with stereotactic body radiation therapy, or SBRT, for those suffering from mesothelioma. SBRT treatments use a device called a linear accelerator that delivers precise and intense doses of[…]

Read More »